FDA To Fast-Track Reviews Of Three Psychedelic Mental Health Drugs
Apr 25
Developing
1
The U.S. Food and Drug Administration this week said it will fast-track reviews of three psychedelic drugs for mental health — MDMA, psilocybin and ibogaine — potentially speeding approval of new treatments nationwide.
